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Introduction 
 
The purpose of this rapid review is to provide NHSScotland with advice on assessment 
of patients with COVID-19 in primary care. 
This guidance is for: general practitioners and primary care teams involved in the 
assessment of patients presenting with potential COVID-19. 
Since the outbreak of coronavirus, there has been an abundance of rapid and systematic 
reviews published on the diagnosis and management of people with symptoms of severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), known as  COVID-19, mostly from 
a secondary care (hospital) perspective. About 80% of people with COVID-19 have symptoms 
which are mild (no pneumonia manifestations) or asymptomatic.1 Others develop severe 
disease (defined as requiring admission to an intensive care unit (ICU)). The challenge for 
primary care practitioners is to identify and triage patients presenting with potential COVID-
19, a disease in which the pattern and duration of symptoms is heterogeneous. This is 
compounded by the need to conduct consultations via telephone or video. In addition, the 
evidence-base is not robust and is subject to change as new evidence emerges.  
The COVID-19 Scottish Primary Care Hub Triage Guide lists the common symptoms, and 
provides red flags for those requiring immediate assessment and yellow flags for those at a 
higher risk of deterioration (eg with certain comorbidities). We conducted a search for new 
evidence on prognostic indicators, risk factors and clinical measures to identify people self-
managing symptoms of COVID-19 in the community whose symptoms may change or worsen, 
and therefore may require monitoring or clinical intervention after their initial presentation to 
primary care. The research question and methodology can be found in section 6. 
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KEY FINDINGS 
 
Primary care clinicians should consider using the COVID-19 Scottish Primary Care Hub 
Triage Guide to inform initial consultations with patients presenting with potential COVID-19. 
Symptoms, characteristics, comorbidities and clinical signs in adults which may indicate a 
higher risk of progression to severe disease: 
 
 The only symptom identified which may distinguish severe disease is shortness of 
breath/dyspnoea. (Table 1) 
 
 Characteristics which have been associated with severe disease are older age, male 
sex and Asian ethnicity.  Older age is the strongest predictor. (Table 2)  
 
 Comorbidities/risk factors most associated with severe disease are hypertension, 
cardiovascular disease, diabetes, obesity, stroke, chronic pulmonary disease, chronic 
kidney disease and cancer. (Table 2)   
 
 No significant associations were found for chronic liver disease. Most studies have 
found no association between smoking and severe disease.  There was no evidence of 
any association between steroids and immunosuppressant medication or angiotensin-
converting enzyme (ACE) inhibitors and angiotensin II receptor (AT1) antagonists but 
very few studies have investigated this. (Table 2)  
 
 No studies investigated the impact of socioeconomic status or frailty. (Table 2) 
 
 Clinical signs which have been found to be associated with severe disease are low 
oxygen saturation levels, low blood pressure and high respiratory rate.  Of these, the 
strongest evidence relates to oxygen saturation levels. (Table 3) 
 
 The evidence base is too weak and emergent to make definitive recommendations. 
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1. Signs and symptoms 
The intention of this evidence review was to identify any evidence of symptoms in adults which 
may differ between mild, moderate and severe disease.  The initial scoping of the evidence 
identified a COVID-19 signs and symptoms tracker which presents severe and non-severe 
symptoms based on early data from China, https://www.cebm.net/covid-19/covid-19-signs-
and-symptoms-tracker/. This was produced by The Centre for Evidence-Based Medicine at 
the University of Oxford and was based on an unpublished systematic review and meta-
analysis.2 Unpublished studies have not been subject to peer review.  We identified a 
published systematic review and meta-analysis which included 43 studies and 3,600 patients 
mostly from China.3 Details of the prevalence of symptoms found in this study are given in 
Table 1. A review, which includes data from the United Kingdom, found little evidence to 
differentiate between mild and moderate symptoms and those in a severe condition.1   
Our rapid review (see section 6) identified 10 published studies and 11 preprints or preliminary 
reports that included data on signs and symptoms from mixed healthcare settings, primarily in 
the United States (US) and Italy.  Most studies are retrospective, observational studies so are 
potentially biased and may not be easily generalisable to Scottish primary care practice.  
Preprint studies have not been subject to peer review.  For these reasons, all evidence 
reported should be considered low quality and needs to be interpreted with caution.  Table 1 
includes the results of the review of published and preprint literature comparing symptoms of 
mild/moderate and severe disease from settings other than China.  It compares them to the 
findings from the recently published systematic review of 43 studies and 3,600 patients mostly 
from China.3  In Table 1 the symptoms listed are those which have been identified as 
associated with COVID-19.  For some symptoms we found no evidence comparing that 
symptom in cases of mild/moderate and severe disease.  This is noted in Table 1.  It is not 
always clear in the literature how the authors define severe disease.  For the purposes of this 
review we considered that disease was severe when a patient was admitted to ICU. In Table 
1 ‘all cases’ means all diagnosed cases and may include mild, moderate and severe disease.  
The severity of disease as a percentage of the diagnosed cases would be likely to vary 
depending on the testing policy in place in that setting at the time the data was collected.  This 
may also result in a higher percentage of confirmed cases in subgroups believed to be at risk 
as they are more likely to have been tested.  
The Chinese meta-analysis provides weak evidence that dyspnoea may be an indicator of 
severe disease as 49% of patients with severe disease experienced dyspnoea compared to 
13% of patients with non-severe disease.3 This finding is supported by evidence from outside 
China where 21 out of 24  patients (88%) in ICU in the US4 experienced shortness of breath 
compared to 5% of  the first 38 diagnosed cases (of any severity) from eight European 
countries5 and 32% of cases confirmed after presenting at an Emergency Department in Italy.6  
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  Table 1: Prevalence of symptoms in mild/moderate and severe COVID-19 
Symptoms 
associated with 
COVID-19 
Prevalence (% of cases - range) 
from studies outside China 
Prevalence (% of cases) 
from meta-analysis – 
mainly China3 
 ICU Hospitalised 
patients 
All 
cases 
Critical illness Non-
critical 
illness 
Cough4-9 88 66–86 16–37 66 57 
Fever > 37.8oC5-7,9-12  28–73 24–85 20–84 81 71 
Dyspnoea4-7,9,13 88 11–80 5–32 49 13 
Fatigue5,10 - 33 21 42 34 
Cough (sputum) No evidence found comparing 
mild/moderate to severe disease  
 
 
32 31 
Delirium (confusion) No evidence found comparing mild/moderate to severe disease. 
Diarrhoea7,10 - 17–27 - 8 4 
Vomiting/nausea6,7,10  - 8–24 8 - - 
Myalgia7,10,13 - 34–42 16 18 21 
Chest pain6,8,13  - - 2–4 - - 
Anosmia/dysgeusia No evidence found comparing mild/moderate to severe disease  
Headache4-6,10 8 17 2–16 11 12 
Dizziness No evidence found comparing mild/moderate to severe disease  
Abdominal pain6,10 - 17 1 - - 
Sore throat4-10,13  8 18–61 1–8 17 11 
 
2. Prognostic Tools 
A variety of risk prediction scores and tools have been developed, which may have use in the 
community. Further research is required for validation and to determine which would be most 
appropriate in a community setting. A summary is available here: https://www.cebm.net/covid-
19/what-prognostic-clinical-risk-prediction-scores-for-covid-19-are-currently-available-for-
use-in-the-community-setting/  
As yet, no trials have been conducted to validate the use of the National Early Warning Score 
(NEWS) or NEWS 2 in the assessment of patients for COVID-19 in primary care.14 However, 
it has been temporarily endorsed by the Royal College of General Practitioners as a response 
to COVID-19 https://elearning.rcgp.org.uk/mod/page/view.php?id=10568 
Five studies of association between co-morbidities or risk factors and hospitalisation for 
COVID-19, severe illness or death were identified.6,11,12,15  Table 2 shows the associations 
noted in these studies as well as ranges of co-morbidities/risk factors identified from the wider 
body of identified studies.  A recent meta-analysis, available as a preprint, summarises 
findings of 63 association studies of which 57 were from China.16 Relevant information from 
this study is also provided in Table 2.  Not all variables are included in all studies and 
considerable risks of confounding remain, which may explain the variation in the results 
reported in these studies. The headings used for the comorbidities/risk factors are those cited 
in the studies and have not been recategorised for this review. 
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Table 2: Comorbidities and risk factors associated with COVID-19 
Comorbidity/risk factor 
Age  
 
Older age 
significantly 
associated with 
severe disease. 
 
 
Older age was reported as significantly associated with severe 
disease in 47 out of 54 studies (87%) in a recent unpublished 
meta-analysis including 17,648 patients with COVID-19, mostly in 
China.16    
 
The average age for hospitalisation reported in studies from the 
US and Italy was 53–68 years, for ICU admission was 63–70 years 
and for death was 77–81 years.4,6,11,12,17-22 
 
An unpublished study examining associations in 4,103 confirmed 
cases in New York found that older age was the strongest 
predictor of hospitalisation.  Age ≥75 years (odds ratio (OR) 66.8, 
95% confidence interval (CI) 44.7 to 102.6) and age 65–74 (OR 
10.9, 95% CI 8.3 to 14.3).  The association was retained albeit 
weakly for critical illness after blood test results on admission were 
included in the analysis: age ≥75 years (OR 2.6, 95% CI 1.6 to 4.1) 
and age 65-74 (OR 1.9, 95% CI 1.2 to 2.9).11  
 
Other studies of association for settings outside China (all 
unpublished) found mixed results. A study of 585 cases in US 
veterans aged 54–75 found age significantly associated with 
hospitalisation but not ICU admission when laboratory findings 
were included in the analysis.12 A study of 2,653 cases in Italy 
found that age was significantly associated with both 
hospitalisation and death.15 A smaller Italian study of 411 cases 
found that older age was significantly associated with death but not 
admission to ICU.6 A small US study (n=54) found that older age 
was significantly associated with hospital admission and 
pneumonia but not if oxygen saturation levels were included in the 
analysis.22 
 
Sex  
 
Male sex  
significantly 
associated with 
severe disease. 
Male sex was reported as significantly associated with severe 
disease in 16 out of 45 studies (36%) which reported on sex in a 
recent unpublished meta-analysis including 17,648 patients with 
COVID-19, mostly in China.16 
 
In studies from Korea, Europe, Italy, USA and Bolivia, males 
accounted for 38–67% of cases, 50–63% of hospital admissions, 
63–93% of severe disease and 56–74% of deaths.4,6,11,17-22 
 
An unpublished study examining associations in 4,103 confirmed 
cases in New York found that there was a significant association 
between male sex and hospitalisation (OR 2.8, 95% CI 2.4 to 3.3) 
but not critical illness once laboratory results were included in the 
analysis.11 Two other unpublished studies from settings outside 
China were identified.  A study of 2,653 cases in Italy found that 
male sex was significantly associated with both hospitalisation and 
death.15  Another Italian study, of 411 cases at a single hospital, 
found that male sex was significantly associated with admission to 
ICU but not death.6 
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Ethnicity  
 
Asian ethnicity 
significantly 
associated with 
severe disease in 
the US. 
There is no mention of ethnicity as a variable of interest in a recent 
unpublished meta-analysis including 17,648 patients with COVID-
19, mostly in China.16  
 
An unpublished study of 4,103 cases in New York found a 
significant association between Asian ethnicity and both 
hospitalisation (OR 1.44, 95% CI 1.04 to 1.98) and critical illness 
(OR 1.91, 95% CI 1.09 to 3.37).  The same study found no 
association between African American ethnicity and hospitalisation 
and a negative association with critical illness (ie African 
Americans were less likely to experience critical illness), OR 0.6, 
95% CI 0.4 to 0.9.11 A further preprint study of 585 cases in a US 
cohort of veterans aged 54–75 found that black ethnicity was 
significantly associated with testing positive for COVID-19 but was 
not associated with hospitalisation or admission to intensive care.12 
 
Socioeconomic 
status 
None of the included studies reported any measure of 
socioeconomic status. However, an ongoing national audit of 
patients critically ill with confirmed COVID-19 in NHS ICUs (not 
including Scotland) has reported a higher proportion of patients 
from more deprived areas than those from less deprived areas.23 
These findings require further investigation and verification. 
 
Obesity  
 
Significantly 
associated with 
severe disease. 
Body mass index (BMI) was reported as significantly associated 
with severe disease in 6 out of 11 studies (55%) in a recent 
unpublished meta-analysis including 17,648 patients with COVID-
19, mostly in China.16 
 
One US study (n=4,103) found that obesity was the most important 
factor for hospitalisation after age; BMI>40 kg/m2 (OR 6.2, 95% CI  
4.2 to 9.3) and BMI 30-40 kg/m2 (OR 4.3, 95% CI 1.9 to 9.2).11 BMI 
was also associated with critical illness; BMI>40 kg/m2 (OR 1.7, 
95% CI 1.0 to 2.9) and BMI 30–40 kg/m2 (OR 1.4, 95% CI 1 to 
1.8).11 An Italian study including 2,653 cases found that obesity 
was not associated with either hospitalisation or death.15  
 
Smoking  
 
Evidence of 
association is 
unclear. 
Being a current smoker was reported as significantly associated 
with severe disease in one out of 11 studies (9%) in the 
unpublished meta-analysis including 17,648 patients with COVID-
19, mostly in China.16 
 
In the association studies identified for settings outside China two 
studies considered smoking.  One study of 585 cases in US 
veterans found no association with hospitalisation or ICU 
admission.12 A study of 4,103 cases in New York found a negative 
association with hospitalisation (OR 0.71, 95% CI 0.57 to 0.87) and 
no association with critical illness.11  A systematic review including 
28 studies concluded that there was low quality evidence that 
current and former smoking compared to never smoking is 
associated with greater disease severity.24 
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Cancer  
 
Significantly 
associated with 
severe disease. 
Cancer was reported as significantly associated with severe 
disease in 5 out of 19 studies (26%) in a recent unpublished meta-
analysis including 17,648 COVID-19 patients, mostly in China.16 
 
Four of the association studies identified from settings outside 
China included cancer in their analysis.  Three studies found no 
association with hospitalisation, admission to ICU or death.6,11,12  
One study of 2,653 cases in Italy found that cancer was associated 
with both hospitalisation (hazard ration(HR) 1.4, 95% CI 1.1 to 1.7) 
and death (HR 1.4,95% CI 1 to 2).15  
 
Cardiovascular 
disease  
 
Significantly 
associated with 
severe disease. 
 
 
Cardiovascular disease 
Cardiovascular disease (CVD) was reported as significantly 
associated with severe disease in 16 out of 25 studies (64%) in a 
large unpublished meta-analysis of mostly Chinese studies.16 After 
age and ‘at least one comorbidity’, CVD and hypertension had the 
strongest association. 
 
An Italian study of 411 cases found CVD had a significant 
association with death but not with ICU admission.6  
 
Hypertension 
Hypertension was reported as significantly associated with severe 
disease in 22 out of 33 studies (67%) and coronary vascular 
disease in 16 out of 25 studies (64%) in the large unpublished 
meta-analysis of mostly Chinese studies.16 After age and any 
comorbidity these two conditions had the strongest association. 
 
Two US studies (n=4,103 and n=585) did not find any significant 
association between hypertension and hospitalisation or critical 
illness.11,12 Two Italian studies (n=2,653 and n=411) found that 
hypertension was significantly associated with both hospitalisation 
and death.6,15 A fifth study (n=54) found hypertension significant for 
hospitalisation and ARDS but that the significance disappeared if 
oxygen saturation was included in the analysis.22 
 
Stroke 
Stroke was also reported as significantly associated with severe 
disease in five out of 12 studies in the systematic review of 
Chinese studies (42%).16 
 
Heart failure 
One Italian (n=2,653) and one US study (n=4,103) found 
significant associations between heart failure and hospitalisation, 
critical illness or death.11,15 
 
Coronary artery disease 
A US study (n=4,103) found no association between coronary 
artery disease and hospitalisation or critical illness.11  
 
Ischaemic heart disease 
One Italian study (n=2,653) found a significant association 
between ischaemic heart disease and both hospitalisation and 
death.15 
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Arrhythmia 
One Italian study (n=2,653) found a significant association 
between arrhythmia and both hospitalisation and death.15 
 
Vascular disease 
Two studies (Italy, n=2,653; US, n=585) found no associations 
between vascular disease and death.12,15 
 
Hyperlipidaemia 
One study (US, n=4,103) found hyperlipidaemia had a negative 
association with hospitalisation but found no association with 
critical illness.11 Another found no association between 
dyslipidaemia and hospitalisation or death.15 
 
ACE inhibitors and AT1 antagonists 
Four of the association studies identified for settings outside China 
included ACE-I and AT1 antagonists in their analysis.  Three 
studies found no association with either hospitalisation or severe 
disease.6,12,22 One study (Italy, n=2,653) found that the medication 
was associated with hospitalisation but not death.15 
  
Chronic kidney 
disease  
 
Significantly 
associated with 
severe disease. 
Chronic kidney disease (CKD) was reported as significantly 
associated with severe disease in four out of 14 studies (29%) in a 
recent unpublished meta-analysis including 17,648 COVID-19 
patients, mostly in China.16  
   
Four of the association studies identified from settings other than 
China included CKD in the analysis.  All found some evidence of 
association with hospitalisation but the picture relating to severe 
disease and death was more mixed.  A study of 4,103 confirmed 
cases in New York found that CKD had the strongest association 
with hospitalisation (OR 3.1, 95% CI 1.8 to 5.5) after age, obesity 
and heart failure.  However, the study found no association for 
critical illness.  Similarly, a study of 2,653 cases in Italy found that 
CKD was associated with hospitalisation (HR 1.9, 95% CI 1.3 to 
2.9) but not death.15 A US study of 585 cases in veterans aged 54–
75 found a significant association for both hospitalisation and ICU 
admission in univariate analyses which was no longer significant 
when laboratory results were added to the analysis.12  An Italian 
study of 411 cases found renal insufficiency to be associated with 
both death and ICU admission.6 
 
Chronic liver 
disease  
 
Has not been 
associated with 
severe disease. 
 
Hepatitis or cirrhosis was reported as significantly associated with 
severe disease in none of the 14 studies in a recent unpublished 
meta-analysis including 17,648 COVID-19 patients, mostly in 
China.16  
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Chronic respiratory 
disease  
 
Evidence of 
association is 
unclear. 
Chronic obstructive pulmonary disease (COPD) was reported as 
significantly associated with severe disease in six out of 19 studies 
(32%) which reported the variable in a recent unpublished meta-
analysis including 17,648 COVID-19 patients, mostly in China.16 
Other respiratory disease was reported as significantly associated 
with severe disease in two out of seven studies (29%) in the same 
meta-analysis. 
 
In unpublished studies from Korea and the USA, the prevalence of 
chronic respiratory disease was 7% in cases, 7–15% in hospital 
admissions, 11–21% in ICU admissions and 17% in patients who 
died.7,11,17,25  
 
Four of the association studies identified from settings other than 
China included pulmonary disease in their analysis.  Results of the 
analysis were mixed.  Two studies found no associations.  A study 
of 4,103 confirmed cases in New York found no association 
between pulmonary disease and hospitalisation or critical illness.11 
A study of 411 cases from one hospital in Italy found pulmonary 
diseases not to be associated with death or admission to ICU.6 
Two studies (US, n=585; Italy n=2,653) found associations with 
hospitalisation but not severe disease or death.12,15  
 
No associations were found for asthma in the single study which 
looked at this separately.12   
 
Diabetes  
 
Significantly 
associated with 
severe disease. 
Diabetes was reported as significantly associated with severe 
disease in 13 out of 32 studies (41%) in the unpublished meta-
analysis including 17,648 COVID-19 patients, mostly in China.16 
    
A US study with 4,103 participants found a significant association 
between diabetes and hospitalisation (OR 2.8, 95% CI 2.1 to 3.7) 
but not critical illness.11 Another US study (n=585) found a 
significant association for hospitalisation but not critical illness.12 
An Italian study (n=2,653) found that diabetes was significantly 
associated with death but not admission to ICU. 
 
Frailty No evidence was identified relating to frailty. 
 
Steroids or other 
Immuno-
suppressants  
 
Evidence of 
association is 
unclear.  
Immunocompromise was considered in only two out of 63 studies 
of association reported in a recent meta-analysis of 17,648 
COVID-19 cases, mostly in China.16 Neither of the studies found 
that it was significantly associated with severe disease.  
 
In two studies from the USA (n=2,026,227 and n=5,143) patients 
on immunosuppressant medications accounted for 3–5% of cases, 
6% of hospital admissions and 6–9% of severe disease.12,25  
 
None of the identified association studies from settings outside 
China included steroids or immunosuppressants in the 
analysis.6,11,12,15,22  
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At least one 
comorbidity  
 
Associated with 
severe disease. 
At least one comorbidity was reported as significantly associated 
with severe disease in 17 out of 23 (74%) studies which reported 
the variable in a recent unpublished meta-analysis including 17, 
648 COVID-19 patients, mostly in China.16  It was second only to 
age as the variable which was reported as significant in the highest 
percentage of studies.    
    
In studies from Singapore, Korea, Italy and USA patients reported 
as having at least one comorbidity accounted for 27–29% of cases, 
71–89% of hospital admissions, 68–78% of severe disease and 
95–99% of deaths.4,6,11,17-22  
 
Only one of the identified association studies included ‘at least one 
comorbidity’ as a variable.  Three other studies looked only at 
individual comorbidities11,12,22 and one used a composite score of 
comorbidity, the Charlson Comorbidity Index.15 A study of 411 
cases presenting at an emergency department in Italy found a 
significant association between any comorbidity and both ICU 
admission and death.6 An Italian study including 2,653 cases found 
a significant association between the Charlson Comorbidity Index 
scores of 1 and death and scores of 2 and 3 or more with both 
death and hospitalisation.15  A higher score represents a greater 
level of comorbidity with 0 representing no comorbid conditions. 
 
 
3. Clinical measures 
Table 3 details clinical measures that were investigated for association with disease severity 
identified in the studies within the review. 
Table 3: Clinical measures considered for identifying symptoms of COVID-19 
Oxygen saturation  
 
Significantly 
associated with 
severe disease. 
Arterial oxygen saturation (SpO2) was reported as significantly 
associated with severe disease in four out of five studies (80%) in 
a recent unpublished meta-analysis including 17,648 patients with 
COVID-19, mostly in China.16 It was unclear whether this was a 
higher or lower oxygen saturation and what level was investigated.  
Saturation levels were not given, nor was it explicitly stated that 
lower oxygen saturation was associated with severe disease, this 
has been assumed. 
 
Three of the identified studies of association from settings outside 
China included oxygen saturation in their analysis.  Results were 
mixed.  One study examining associations in 4,103 confirmed 
cases of COVID-19 in New York found that oxygen saturation at 
levels <88% and 88–92% were strongly associated with critical 
illness compared to levels >92% (OR 6.99, 95% CI 4.5 to 11 at 
88% and OR 1.48, 95% CI 1.09 to 2.01 at 88–92%).11 A US study 
of 585 veterans aged 54–75 found that a 1% reduction in SpO2 
was not associated with hospitalisation or admission to ICU.12 The 
final study of 54 patients in California found that SpO2 was 
significantly associated with hospitalisation and development of 
pneumonia and ARDS but not admission to ICU.22 
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Respiratory rate 
 
Significantly 
associated with 
severe disease. 
Respiratory rate was reported as significantly associated with 
severe disease in six out of 10 studies (60%) in a recent 
unpublished meta-analysis including 17,648 patients with COVID-
19, mostly in China.16 It is unclear what level was investigated for 
significance. 
 
None of the identified studies of association from settings outside 
China included respiratory rate in their analysis. 
 
Heart rate 
 
Evidence of 
association is 
unclear. 
Heart rate was reported as significantly associated with severe 
disease in one out of seven studies (14%) in a recent unpublished 
meta-analysis including 17,648 patients with COVID-19, mostly in 
China.16  It is unclear what level of increase was investigated for 
significance. 
 
An Italian study of 2,653 cases found a small negative association 
with increased heart rate and hospitalisation but no association 
with admission to ICU.15 
 
Systolic blood 
pressure  
 
Significantly 
associated with 
severe disease. 
Systolic blood pressure (SBP) was reported as significantly 
associated with severe disease in two out of five studies (40%) in a 
recent unpublished meta-analysis including 17,648 patients with 
COVID-19, mostly in China.16  It is unclear whether this was higher 
or lower SBP and what level was investigated for significance. 
 
Of the identified studies of association in settings outside China, 
one US study (n=585) found that a 5mm Hg decrease in SBP was 
associated with hospitalisation (OR 1.1, 95% CI 1 to 1.2) but not 
with ICU admission.12 
 
 
4. Method of patient consultation 
No validated method of measuring breathlessness via tele- or video consultations has been 
identified. A recommendation based on the consensus of 50 clinicians advises against using 
the Roth test.26 Questions like those in the COVID-19 Scottish Primary Care Hub Triage Guide 
can be asked. Smartphone apps should not be used as oximeters.27  
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5. Sources of further information 
For up-to-date information on signs, symptoms and prognosis of COVID-19, the following 
websites provide summaries of new evidence which are updated frequently: 
BMJ Best practice: https://bestpractice.bmj.com/topics/en-gb/3000168/prognosis 
Centre for Evidence-Based Medicine, University of Oxford, provides rapid reviews of 
research, categorised under ‘Signs and Symptoms’, ‘Symptom Assessment’ and ‘Diagnostic 
Tests’: https://www.cebm.net/oxford-covid-19-evidence-service/ 
National Institute for Health and Care Excellence (NICE): https://www.nice.org.uk/covid-
19 
UptoDate: https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-
epidemiology-virology-clinical-features-diagnosis-and-prevention#H3432457140 
 
Guidance and further information on management, care and service delivery in relation to 
COVID-19 is signposted from the Scottish Intercollegiate Guidelines Network (SIGN) 
website: www.sign.ac.uk 
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6. Methodology 
 
6.1 Key question 
This rapid review is based on a structured key question that defines the target population, the 
intervention or exposure under investigation and the outcomes used to measure efficacy, 
effectiveness, or risk. This question formed the basis of the literature search. 
In people presenting in primary care with potential COVID-19, which are the best 
predictors of adverse outcomes, such as hospitalisation and ventilation therapy? 
Population Interventions/Exposures Outcomes Notes 
 
People in the 
community 
presenting to 
primary care with 
potential COVID-
19 
 
For search 
purposes include 
all people 
presenting with 
potential 
COVID19 
including hospital-
based studies 
given lack of 
studies in the 
population of 
interest. 
 
 
 
 
 
 
Sociodemographic factors: 
age, gender, ethnicity, 
socioeconomic status. 
 
Health-related behaviours:  
smoking, alcohol intake 
 
Clinical information: 
comorbidities, current 
medications, 
previous medical history, 
BMI, 
blood pressure, 
signs on clinical examination 
(temperature, pulse, 
respiratory rate), 
onset of new symptoms (eg 
cough, temperature >37.8°C, 
fatigue, sputum, shortness of 
breath, muscle aches, sore 
throat, headache, chills, nasal 
congestion, nausea, diarrhoea) 
 
development of symptoms, 
symptom progression, 
symptom duration, 
combination of symptoms.  
 
Disease severity 
Admission to hospital 
Admission to ICU 
Mechanical 
ventilation 
Mortality 
Duration of 
symptoms  
Disease progression  
 
 
 
Consider method of 
consultation: 
telephone, video, face-
to-face and whether 
different assessments 
need to be considered 
for each. 
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6.2 Literature review 
A topic exploration was conducted to identify relevant guidance, systematic reviews and 
rapid reviews, using a broad internet search including, but not exclusively, the following 
websites: 
BMJ Evidence, Center for Disease Control and Prevention, Cochrane Library, Dynamed, 
MAGICApp, McMasterforum, Medrxiv, National Institute for Health and Care Excellence, 
Oxford Centre for Evidence Based Medicine, TRIP database, Uptodate, World Health 
Organization.  
A systematic search was conducted for primary sources of evidence using Medline and 
Embase.  MedRXiv was searched for preprints added up to and including 24 April 2020.  No 
quality assessment was carried out as all evidence is likely to be low quality given that only 
early data is available.  
 
6.3 Updating the review 
Scoping searches for new evidence will be conducted every two months. The review will be 
updated if new evidence emerges that changes the current conclusions.  
 
6.4 Contributors 
 Ms Janet Bouttell 
(Main author) 
Research Assistant, University of Glasgow 
 Dr David Blane General Practitioner, NHS Greater Glasgow and 
Clyde; Clinical Research Fellow in General Practice 
and Primary Care, University of Glasgow 
 Mr Ryan Field PhD student, University of Glasgow 
 Mr Robert Heggie Research Assistant, University of Glasgow 
 Dr Bhautesh Jani General Practitioner, NHS Lanarkshire and NHS 
Greater Glasgow and Clyde; Clinical Senior Lecturer 
in Primary Care, University of Glasgow   
 Ms Joanna Kelly Senior Health Services Researcher, Healthcare 
Improvement Scotland 
 Ms Karen MacPherson Lead Health Services Researcher, Healthcare 
Improvement Scotland 
 Professor Kate O’Donnell 
 
 
Professor of Primary Care Research and 
Development, University of Glasgow 
 
 Ms Dikshyanta Rana Research Assistant, University of Glasgow 
 Ms Gaynor Rattary Guideline Coordinator, SIGN 
 Dr Carolyn Sleith Information Scientist, Healthcare Improvement 
Scotland 
 Ms Ailsa Stein Programme Manager, SIGN 
 Professor Olivia Wu Professor of Health Technology Assessment, 
University of Glasgow 
 
Each contributor completed a declaration of interests form. No competing interests were 
identified. 
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6.5 Peer review 
General practitioners, an epidemiologist, and a lay representative were invited to comment 
on a draft version of this report, to consider the interpretation of the evidence and feasibility 
for practice.  
SIGN is grateful to these experts for their contribution. 
Dr Neave Corcoran General Practitioner, NHS Lothian 
Dr Kate Dawson General Practitioner, Benbecula Medical Practice, 
Benbecula 
Dr Ciara Drummond General Practitioner Locum, Bearsden 
Dr Robert Duncan General Practitioner, St Ronans Practice, Innerleithen 
Dr Hamish Foster MRC Clinical Research Training Fellow, University of 
Glasgow 
Dr Katie Gallacher Stroke Association Senior Clinical Lecturer, University of 
Glasgow 
Professor Phil Hannaford Professor of Primary Care, University of Aberdeen 
Dr David Hogg GP Principal, Lauderdale Medical Practice, Dunbar 
Dr Neil Houston General Practitioner, Dollar Health Centre, Dollar 
Dr Scott Jamieson General Practitioner, Kirriemuir Medical Practice, 
Kirriemuir 
Dr Carey Lunan Chair of Royal College of General Practitioners, 
Edinburgh 
Dr Frances Mair Norie Miller Professor of General Practice, University of 
Glasgow 
Dr Marianne McCallum General Practitioner, The Tannahill Surgery, Paisley 
Dr Margaret McCartney General Practitioner, Glasgow, Honorary Fellow at the 
Centre of Evidence Based Medicine, Oxford 
Dr Paul Ryan General Practitioner, Glenmill Medical Practice, Glasgow 
 
6.6 Editorial 
As a final quality check, the guideline is reviewed by an editorial group, as follows: 
Dr Roberta James Programme Lead, SIGN 
Dr Safia Qureshi Director of Evidence, Healthcare Improvement Scotland 
Professor Angela Timoney Chair of SIGN 
 
Abbreviations 
ACE angiotensin-converting enzyme  
 
ARDS acute respiratory distress syndrome 
 
AT1 angiotensin-II receptor antagonists/angiotensin receptor blockers 
 
BMI body mass index 
 
CI confidence interval 
 
CKD chronic kidney disease 
 
COPD chronic obstructive pulmonary disease 
 
CVD cardiovascular disease 
 
HR hazard ratio 
 
ICU intensive care unit 
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NEWS National Early Warning Score 
 
NICE National Institute for Health and Care Excellence 
 
OR odds ratio 
 
SaO2 arterial oxygen saturation 
 
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 
 
SBP systolic blood pressure 
 
SIGN Scottish Intercollegiate Guidelines Network 
 
US United States 
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